90 related articles for article (PubMed ID: 1492863)
1. [Controlled study of the effect of dihydroergocristine on organic brain psychosyndrome].
Aranda B; Dumoulin P; Groothold G
Arzneimittelforschung; 1992 Nov; 42(11A):1406-9. PubMed ID: 1492863
[TBL] [Abstract][Full Text] [Related]
2. [Dihydroergocristine in organic brain psychosyndrome. Multicenter placebo-controlled clinical double-blind study in 240 patients].
Lazzaroni M; Cattalini C; Massetto N; Poli A
Arzneimittelforschung; 1992 Nov; 42(11A):1410-3. PubMed ID: 1492864
[TBL] [Abstract][Full Text] [Related]
3. [Dihydroergocristine in the treatment of organic brain psychosyndrome. Dose-finding study against placebo].
Milvio C
Arzneimittelforschung; 1992 Nov; 42(11A):1399-402. PubMed ID: 1492861
[TBL] [Abstract][Full Text] [Related]
4. [One-year therapy with dihydroergocristine for treatment of impaired alertness and memory in elderly patients. Placebo-controlled multicenter study].
Agliati G; Lazzaroni M; Mariani G; Marras F; Massetto N; Menozzi C; Ortenzi E; Perna G; Puppo N; Santambrogio S
Arzneimittelforschung; 1992 Nov; 42(11A):1414-6. PubMed ID: 1492865
[TBL] [Abstract][Full Text] [Related]
5. Confirmed clinical efficacy of Actovegin in elderly patients with organic brain syndrome.
Kanowski S; Kinzler E; Lehmann E; Schweizer A; Kuntz G
Pharmacopsychiatry; 1995 Jul; 28(4):125-33. PubMed ID: 7491366
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
7. Dihydroergocryptine in the management of senile psycho-organic syndrome.
Scarzella L; Bono G; Bergamasco B
Int J Clin Pharmacol Res; 1992; 12(1):37-46. PubMed ID: 1526697
[TBL] [Abstract][Full Text] [Related]
8. [The effect of dihydroergocristine on cognitive functions and sleep in elderly subjects].
Bramanti P; Ricci RM; Mailland F; Di Perri R
Arzneimittelforschung; 1992 Nov; 42(11A):1403-6. PubMed ID: 1492862
[TBL] [Abstract][Full Text] [Related]
9. [Epidemiologic study on the effectiveness and safety of dihydroergocristine in impaired memory and behavioral functions in aged humans].
Abate G; Angeleri F; Bartorelli L; Battistin L; Bergamasco B; Bertolini S; Bulfoni A; Capurso A; Cazzato G; Coccagna G
Arzneimittelforschung; 1992 Nov; 42(11A):1417-21. PubMed ID: 1492866
[TBL] [Abstract][Full Text] [Related]
10. [The effect of Ginkgo biloba extract on neurophysiological and psychometric measurement results in patients with psychotic organic brain syndrome. A double-blind study against placebo].
Hofferberth B
Arzneimittelforschung; 1989 Aug; 39(8):918-22. PubMed ID: 2684175
[TBL] [Abstract][Full Text] [Related]
11. Nylidrin HCL in the treatment of symptoms of the aged: a double-blind placebo controlled study.
Goldstein SE; Birnbom F
J Clin Psychiatry; 1979 Dec; 40(12):520-4. PubMed ID: 500575
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
13. Double-blind trial of suloctidil versus placebo in moderate to severe mental deterioration.
Baro F; Malfroid M; Waegemans T; Cox JP
Pharmatherapeutica; 1985; 4(6):399-404. PubMed ID: 3001778
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of phospholipid liposomes in the treatment of neuropsychological disorders associated with the menopause: a double-blind, randomised, placebo-controlled study.
Rachev E; Nalbansky B; Kolarov G; Agrosì M
Curr Med Res Opin; 2001; 17(2):105-10. PubMed ID: 11759177
[TBL] [Abstract][Full Text] [Related]
15. On the effects of pyritinol on functional deficits of patients with organic mental disorders.
Herrmann WM; Kern U; Röhmel J
Pharmacopsychiatry; 1986 Sep; 19(5):378-85. PubMed ID: 3534901
[TBL] [Abstract][Full Text] [Related]
16. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J
Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial.
Ditzler K
Arzneimittelforschung; 1991 Aug; 41(8):773-80. PubMed ID: 1781796
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of disorders of cerebral performance in the aged in ambulatory care using bencyclane. Results of a controlled double-blind phase III study versus placebo].
Garweg G; Herrmann WM; Kern U
Z Gerontol; 1987; 20(1):56-62. PubMed ID: 3554804
[TBL] [Abstract][Full Text] [Related]
20. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
